Search
Fluticasone propionate
go.drugbank.com/drugs/DB00588ApprovedInvestigationalThese drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].
Mixtures: HOVID CLEFAN-S POWDER FOR INHALATION 50/250MCG, AIRFLUSAL FORSPIRO POWDER FOR INHALATION 50MCG/500MCGCategories: Corticosteroids for inhalation useKetotifen
go.drugbank.com/drugs/DB00920ApprovedInvestigationalavailable and indicated as an add-on therapy for children with atopic asthma. … [A231204] Ketotifen was first developed in Switzerland in 1970 by Sandoz Pharmaceuticals and was initially marketed for the treatment of anaphylaxis.
Categories: Antihistamines for Systemic UseMogamulizumab
go.drugbank.com/drugs/DB12498ApprovedInvestigationalMogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of … [L4168] It was approved for the same indications in Canada in June 2022.
Categories: Chemokine Receptor Type 4 Interaction, Chemokine Receptor Type 4 InteractionsPefloxacin
go.drugbank.com/drugs/DB00487ApprovedA synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigationalCasirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19. … They are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA.
Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19Azilsartan medoxomil
go.drugbank.com/drugs/DB08822ApprovedInvestigationalAs hypertension is a major risk factor for cardiovascular disease,[A7354] early management of hypertension has several implications on patients' survival rate and quality of life in the future. … therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for
Categories: Antihypertensive Agents Indicated for Hypertension, Angiotensin 2 Receptor BlockerOteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] Unlike previous-generation azole antifungals, oteseconazole has a high selectivity for CYP51 and little interaction with human cytochrome P450s.
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseBromodiphenhydramine
go.drugbank.com/drugs/DB01237ApprovedBromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. Ethanolamine antihistamines produce marked sedation in most patients.
Categories: Antihistamines for Systemic UseDelavirdine
go.drugbank.com/drugs/DB00705ApprovedInvestigationalWithdrawnA potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigationalIstradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. … [A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia.
Categories: Adenosine A2 Receptor Antagonists, Purinergic P1 Receptor Antagonists